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Neuroblastoma is the most common extra-cranial solid 
tumor of childhood and it is characterized by the pres-
ence of a glycosphingolipid, GD2 ganglioside. Monoclo-
nal antibodies targeting the antigen are currently tested 
in clinical trials. Additionally, several research groups 
reported results revealing that ganglioside-specific an-
tibodies can affect cellular signaling and cause direct 
cytotoxicity against tumor cells. To shed more light on 
gene expression signatures of tumor cells, we used mi-
croarrays to analyze changes of transcriptome in IMR-32 
human neuroblastoma cell cultures treated with doxoru-
bicin (DOX) or a mouse monoclonal antibody binding to 
GD2 ganglioside 14G2a (mAb) for 24 h. The obtained re-
sults highlight that disparate cellular pathways are regu-
lated by doxorubicin and 14G2a. Next, we used RT-PCR 
to verify mRNA levels of selected DOX-responsive genes 
such as RPS27L, PPM1D, SESN1, CDKN1A, TNFSF10B, and 
14G2a-responsive genes such as SVIL, JUN, RASSF6, TLX2, 
ID1. Then, we applied western blot and analyzed levels 
of RPS27L, PPM1D, sestrin 1 proteins after DOX-treat-
ment. Additionally, we aimed to measure effects of dox-
orubicin and topotecan (TPT) and 14G2a on expression 
of a novel human NDUFAF2 gene encoding for mimitin 
protein (MYC-induced mitochondrial protein) and cor-
relate it with expression of the MYCN gene. We showed 
that expression of both genes was concomitantly de-
creased in the 14G2a-treated IMR-32 cells after 24 h and 
48 h. Our results extend knowledge on gene expression 
profiles after application of DOX and 14G2a in our mod-
el and reveal promising candidates for further research 
aimed at finding novel anti-neuroblastoma targets.
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INTRODUCTION
Neuroblastoma is the most common extra-cranial sol-
id tumor diagnosed in childhood and the disease shows 
a remarkable biological heterogeneity (Øra & Eggert, 
2011). Hence, a high rate of spontaneous regressions can 
be observed in infants with the 4S stage of the disease 
(Brodeur & Bagatell, 2014). On the contrary, an im-
provement of outcomes of patients with high risk neuro-
blastoma still remains a major challenge for pediatric on-
cologists (Moreno et al., 2013). Neuroblastoma cells are 
marked with presence of GD2 ganglioside and tests of 
passive administration of monoclonal antibodies target-
ing the tumor-associated antigen are clinically advanced. 
Recently, Yu et al., reported that addition of a chimeric 
monoclonal antibody ch14.18 binding GD2 ganglioside, 
IL-2, and GM-CSF to 13-cis retinoic acid is effective in 
children with high risk neuroblastoma (Yu et al., 2010).
Several research reports establish clearly that bind-
ing of ganglioside-specific antibodies can affect fate of 
cancer cells, e.g., lead to changes in cellular signaling 
and induce cell death that may encompass apoptosis, 
necrosis, and oncosis-like mechanisms (for review on 
the topic see Horwacik & Rokita, 2015). In 2009, our 
group showed that a mouse monoclonal antibody (mAb) 
14G2a caused cell death with partial involvement of ap-
optosis in cultures of a human neuroblastoma cell line 
IMR-32, as evidenced by a rise in staining with Annexin 
V and propidium iodide and an increase in caspase 3 
activity (Kowalczyk et al., 2009). Moreover, synergistic 
effects were observed when 14G2a was combined with 
standard chemotherapeutic drugs such as doxorubicin 
(DOX) that is an anthracycline antibiotic blocking activ-
ity of topoisomerase II, and topotecan (TPT) that is a 
camptothecan analogue and an inhibitor of topoisomer-
ase I (Kowalczyk et al., 2009).
Biology of neuroblastoma is being intensively studied. 
MYCN amplification is an independent negative prog-
nostic factor in neuroblastoma. Additionally, high ex-
pression levels of aurora A kinase were shown to indi-
cate a shorter survival in neuroblastoma patients (Rama-
ni et al., 2015). In 2013, our group showed that aurora A 
and MYCN oncogenic proteins are decreased upon the 
14G2a-treatment of IMR-32, which correlated with an 
increase of a tumor suppressor protein P53. Moreover, 
the antibody enhanced effects of an aurora A inhibitor, 
MK-5108, and 13-cis retinoic acid in some MYCN-am-
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plified neuroblastoma cell lines (Horwacik et al., 2013). 
This fuels our efforts to characterize more deeply ef-
fects of the 14G2a mAb on survival of the tumor cells. 
Therefore, primarily we focused our experiments to de-
cipher changes in expression of genes in IMR-32 cells 
treated with 14G2a using microarrays. Also, we aimed 
to compare the changes of transcriptome in 14G2a-
treated cells to doxorubicin-treated cells. Previously, the 
chemotherapeutic drug had been shown by us to act 
synergistically with 14G2a on IMR-32 cells (Kowalczyk 
et al., 2009). Then, based on the microarray results, we 
intended to analyze expression of selected 14G2a- and 
doxorubicin-responsive genes by RT-PCR and western 
blot techniques. Finally, we wanted to analyze changes 
in expression of NDUFAF2 upon addition of 14G2a, 
doxorubicin or topotecan to IMR-32 cells.
Here, we present result of microarray analyses of 
changes in transcriptome of IMR-32 cells treated with 
14G2a or DOX for 24 h. Gene ontology (GO) analy-
sis showed that genes regulated by DOX are involved 
in such cellular processes as induction and positive reg-
ulation of cell death (including apoptosis), DNA meta-
bolic processes, negative regulation of cell proliferation, 
and response to UV. This contrasts with genes regu-
lated by 14G2a which were assigned to a single group 
of genes involved in regulation of RNA metabolic pro-
cesses. Although the results generated with microarrays 
had showed rather limited changes in mRNA profiles, 
they allowed us to select new gene candidates for fur-
ther research. Thus, expression patterns of some selected 
genes: RPS27L, PPM1D, SESN1, CDKN1A, TNFS-
F10B, SVIL, JUN, RASSF6, TLX2, ID1 were analyzed 
in our model by application of RT-PCR and/or western 
blot techniques. Also, we showed a correlation between 
changes of expression of a NDUFAF2 gene encoding 
for mimitin (MYC-induced mitochondrial protein) and 
the MYCN gene in the 14G2a-treated IMR-32 cells. The 
performed experiments allowed us to gain more insight 
into gene regulation in IMR-32 cells after treatment with 
14G2a and DOX. Literature search on 14G2a-respon-
sive genes allowed us to conclude that on one side the 
antibody affects pathways already established as impor-
tant for neuroblastoma biology, on the other side novel 
gene candidates can be selected for further analyses.
MATERIALS AND METHODS
Cell culture and treatment with doxorubicin and 
14G2a mAb. Cell culture of IMR-32 (ATCC, USA, 
CCL-127), KELLY (Leibniz-Institut DSMZ – Deutsche 
Sammlung von Mikroorganismen und Zellkulturen 
GmbH, Germany, ACC 355), both MYCN-amplified hu-
man neuroblastoma cells, a MYCN-non-amplified SK-
N-SH human neuroblastoma cells (ATCC, HTB-11), a 
hybridoma cell line producing the 14G2a mAb (kindly 
provided by Dr. R. Reisfeld, The Scripps Research In-
stitute, La Jolla, CA, USA), purification of the 14G2a 
mAb, treatment of IMR-32 cells with doxorubicin, to-
potecan, and 14G2a were previously described in de-
tails (Horwacik et al., 2013; Kowalczyk et al., 2009). For 
most of the experiments IMR-32 cells were used. Briefly, 
IMR-32 cells were grown in EMEM containing 1% non-
essential amino acid solution, 1 mM sodium pyruvate, 50 
mg/ml of gentamicin (all from Sigma-Aldrich, Poland), 
supplemented with 10% fetal calf serum (Life Technol-
ogies, Poland) at 37ºC, and in an atmosphere contain-
ing 5% CO2. The cells were treated with doxorubicin, 
14G2a mAb, or both agents for a given time (see the 
Results). Control cells were also included in experiments. 
The concentration of doxorubicin was 15 nM for micro-
array studies, 15 nM, 17 nM and 30 nM for RT-PCR 
and western blot studies (see the Results). The 14G2a 
mAb was used at concentration of 40 μg/ml for all re-
sults presented below. In some experiments cells were 
treated with 2 nM topotecan. The effects of the drugs 
on the IMR-32 cells were measured using cell viability 
tests, i.e., MTT tests (Sigma-Aldrich) or ATPlite Lumi-
nescence ATP Detection Assay System (Perkin Elmer, 
USA) according to instructions from manufacturers.
Microarray hybridization. Microarray hybridiza-
tion was performed by Genbioinfo (Krakow, Poland). 
Total RNA was isolated using the TRIZOL reagent ac-
cording to the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). RNA concentration was measured using 
a ND-1000 Spectrometer (NanoDrop Technologies Inc., 
Montchanin, DE, USA). RNA quality was determined 
using an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, 
CA, USA). A starting amount of 200 ng of high-quality 
total RNA was used to generate cDNA and cRNA with 
the Illumina TotalPrep RNA Amplification Kit (Illumina, 
San Diego, CA, USA). The procedure consisted of RT 
with an oligo(dT) primer bearing a T7 promoter using 
Array-Script. The obtained cDNA became a template for 
in vitro transcription with T7 RNA polymerase and bio-
tin UTP, which generated multiple copies of biotinylated 
cRNA. The purity and concentration of the cRNA were 
determined using a NanoDrop ND-1000 Spectrom-
eter. Quality cRNA was subsequently hybridized using 
a direct hybridization array kit (Illumina). Each cRNA 
sample (1.5 μg) was hybridized overnight using the Hu-
manHT-12 BeadChip array (Illumina) in a multiple-step 
procedure; the chips were washed, dried, and scanned on 
the BeadArray Reader (Illumina). Raw microarray data 
were generated using BeadStudio v3.0 (Illumina). A total 
of 12 Illumina HumanHT-12v3 microarrays were used in 
the experiment.
Microarray data analysis. Microarray data analysis 
was performed by Genbioinfo (as shown on data pre-
sented on Fig. 1, Table 1–3). Microarray analysis and 
quality control of the arrays were performed using Bea-
dArray R package v1.0.0. After background subtraction 
(using median background method), the data were nor-
malized using quintile normalization and were subse-
quently log2-transformed. The obtained signal was taken 
as the measure of mRNA abundance derived from the 
level of gene (or particular transcriptional form) expres-
sion. The following criteria were applied for probe-set 
detection: at least three samples with signal intensity >7.4 
(log2 data). This reduced the number on the analyzed 
probes to 19 642 (from total 49 895). Two-Way ANOVA 
was applied to calculate significance levels (P values) to 
discriminate differentially expressed genes between con-
trols and the treated groups. The false discovery rate 
(FDR) was estimated using the Benjamini and Hochberg 
method. All statistical analyses were performed using R 
software version 2.10.1. Hierarchical clustering was per-
formed with dChip software using Euclidean distance 
and average linkage method. The Database for Anno-
tation, Visualization and Integrated Discovery (DAVID 
2.1), a functional annotation analysis tool, was used to 
identify over-represented ontological groups among gene 
expression profiles and to group genes into functional 
classifications (with default options).
Determination of levels of selected transcripts 
with RT-PCR. RNA isolation, cDNA production from 
DOX-, TPT-, 14G2a-treated and control cells were per-
formed as described previously (Horwacik et al., 2013; 
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Kowalczyk et al., 2009). From 1 to 4 mg of total RNA 
was used in reactions with reverse transcriptase. MYCN 
primers were from Stock et al. (Stock et al., 2008), ACTB 
primers were from Kowalczyk et al. (Kowalczyk et al., 
2005), EF2-1 primers were from Skalniak et al. (Skalniak 
et al., 2014), MYC primers were from Wang et al. (Wang 
et al., 2008). Other primers were designed using Prim-
er-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) or Primer3web version 4.0.0 software (Koressaar 
and Remm, 2007; Untergrasser et al., 2012, http://prim-
er3.sourceforge.net) and their annealing temperatures 
were optimized empirically (sequences of primers from 
5’ to 3’, product sizes of amplicons, and annealing tem-
peratures of primers are listed below): For semiquantita-
tive RT-PCR following primers were used: CDKN1A-1 
(F:CTGCCCAAGCTCTACCTTCC, R: CAGGTCCA-
CATGGTCTTCCT, product size 123 bp, annealing temp. 
57ºC), RPS27L (F: TGCCGAGCGCAGATCGCTTG, 
R: TGGCCTTTCCTCCTGTAGGCTGG, product size 
294 bp, annealing temp. 61ºC), SESN1 (F: CTTCTG-
GAGGCAGTTCAAGC, R: TGAATGGCAGCCT-
GTCTTCAC, product size 341 bp, annealing temp. 
59ºC), TNFRSF10B (F: GGCCCCACAACAAAAGAG-
GTCCA, R: CCCCAGGTCGTTGTGAGCTTCTG, 
product size 599 bp, annealing temp. 65ºC), PPM1D 
(F: TTCTCGCTTGTCACCTTGCC, R: CCAAACTA-
CACGATTCACCCC, product size 302, annealing temp. 
59ºC), MYC (F: TCAAGAGGCGAACACACAAC, R: 
GGCCTTTTCATTGTTTTCCA, product size 110 bp, 
annealing temp. 57ºC). For normalization of amounts of 
samples , cDNA of ACTB was measured using primers 
ACTB (F: AGCGGGAAATCGTGCGTG, R: GGGTA-
CATGGTGGTGCCG, product size 307 bp, annealing 
temp. 55ºC). Primers used for qtRT-PCR were as fol-
lows: NDUFAF2 (F: GCAGGGGATATTCCAACAGA, 
R: GCAGGAGTTCCTCACTGGTC, product size 173 
bp, annealing temp. 55ºC), MYCN (F: ACCACAAGGC-
CCTCAGTACCT, R: GTGGTGACAGCCTTGGT-
GTTG, product size 144 bp, annealing temp. 60ºC), ID1 
(F: TCAGCACCCTCAACGGCGAGAT, CCAGGTAC-
CCGCAAGGATGGGA, product size 150 bp, annealing 
temp. 62ºC), SVIL (F: GGTGTGGAAGAGCCGGGT-
AGA, R: AGTCCTCAAGGCCATCCACTTGAA, prod-
uct size 149 bp, annealing temp. 62ºC), CDKN1A-2 (F: 
CAGCTGCTGCAACCACAGGGATTT, R: CATCA-
CAGTCGCGGCTCAGCT, product size 146 bp, anneal-
ing temp. 62 ºC), RASSF4 (F: TAAGACCTCCGTGTT-
TACTCCA, R: GATGTAGAGTGCGAACTCACTG, 
product size 150 bp, annealing temp. 60ºC), JUN (F: 
TCCAAGTGCCGAAAAAGGAAG, R: CGAGTTCT-
GAGCTTTCAAGGT, product size 156 bp, anneal-
ing temp. 60ºC), TLX2 (F: TGAGGGGCTCTAGCG-
GCGTT, R: AATCAGCCAGCCTCTCGCGC, product 
size 115 bp, annealing temp. 60ºC). EF2-1 (F: GA-
CATCACCAAGGGTGTGCAG, R: TCAGCACACTG-
GCATAGAGGC, product size 214 bp, annealing temp. 
62ºC), or EF2-2 primers (F: GGTGCAGTGCATCATC-
GAGGAGTC, R: TCGCGGTACGAGACGACCGG, 
144 bp, annealing temp. 62ºC) were used to measure ref-
erence cDNA.
Western blotting analyses of protein expression. 
Whole cell protein extracts were prepared, resolved us-
ing SDS/PAGE, and expression levels of particular pro-
teins were determined using a western blot technique as 
described previously in details (Kowalczyk et al., 2009; 
Horwacik et al., 2013). For detection and quantification 
of particular proteins we optimized empirically: meth-
ods of isolation of proteins, amounts of cellular proteins 
and particular antibodies used for western blotting. Fol-
lowing primary antibodies were used: rabbit polyclonal 
anti-sestrin 1 antibodies (1:10 000 dilution, SAB1401644, 
Sigma-Aldrich), and rabbit polyclonal anti-RPS27L anti-
bodies (1:3 000 dilution, SAB4502097, Sigma-Aldrich), 
a mouse monoclonal anti-GAPDH antibody (G-8795, 
30 000–40 000 times diluted, dilution, Sigma-Aldrich), 
a mouse monoclonal anti-PPM1D (WIP1) antibody 
(WH0008493M1, 0.167–1.0 µg/ml, Sigma-Aldrich), goat 
anti-mimitin polyclonal antibodies (sc:50098, 1:200 dilu-
tion, Santa Cruz Biotechnology, USA), rabbit polyclonal 
anti-MYCN antibodies (sc: 791, 1:200 dilution, Santa 
Cruz Biotechnology), a mouse anti-c-MYC monoclonal 
antibody (sc:42, 1:200 dilution, Santa Cruz Biotechnol-
ogy), and anti-α-tubulin antibody (#2125S; 1:1 000 di-
lution; Cell Signaling, USA). Secondary HRP conjugate 
antibodies used were as follows: goat anti-rabbit IgG 
polyclonal antibodies (A-0545, 10 000–20 000 times di-
luted, Sigma-Aldrich), rabbit anti-mouse IgG antibodies 
(A-9044, 20 000–40 000 times diluted, Sigma-Aldrich), 
rabbit anti-goat IgG antibodies (A-5420, 1:20 000, Sigma-
Aldrich), and goat anti-rabbit IgG (#7074, 1:2 000, Cell 
Signaling). Samples were normalized using reference sig-
nal from binding of the anti-GAPDH or anti-α tubulin 
antibodies.
Statistical analyses. Data on graphs on Figs 3–5 
are shown as means with SEM (standard errors of the 
means). Statistical significance between signals of con-
trols and drug-treated samples were analyzed using pair-
wise t tests (Excel, Microsoft Office). For analysis of 
time-dependence of signals on the graphs presented on 
the Fig. 4 and the Fig. 5, we applied one-way ANOVA 
with repeats using R software (R version 2.15.1 Patched), 
*P<0.05, **P<0.01, ***P<0.001.
RESULTS
Microarray analyses of IMR-32 cells treated with DOX 
and 14G2a
We performed research to extend our knowledge on 
mechanism involved in cell death upon binding of the 
14G2a mAb to neuroblastoma cells. We used microarray 
technology to decipher changes in expression of genes 
in the model of MYCN-amplified IMR-32 cells treated 
with 14G2a mAb, and compared them to a standard 
chemotherapeutic drug, doxorubicin. 12 sets of Illumina 
HT-12v3 microarrays were used to analyze 3 independ-
ent experiments consisting of control cells, and cells 
treated for 24 h with 15 nM doxorubicin, 40 μg/ml of 
14G2a, and both agents. Data analyses were performed 
on 19 642 probes from a total number of 49 895 probes. 
The list of probes, obtained with ANOVA at FDR<5%, 
showing response to doxorubicin contains 46 positions 
(see Table 1 for the list and Fig. 1A that shows a hierar-
chical clustering of the doxorubicin-responsive genes and 
particular transcriptional forms). The list of transcripts 
affected by 14G2a contains 28 positions (see Table 2 for 
the list and Fig. 1B that shows a hierarchical clustering 
of 14G2a-responive genes or particular transcriptional 
forms, ANOVA at FDR<5%). For the probes changed 
after treatment with DOX we measured increase of sig-
nal in the range from about 1.1–2.8 as compared to con-
trol cells. Particularly, an increase of ≥1.5 was measured 
for: CDKN1A, ACTA2, RN7SK, SESN1, TNFSF10B, 
RPS27L, BAX, PHLDA3, GADD45 and 2 sequences 
HS.545589 and HS.193406 (see Table 1). For the rest of 
probes changes between 1.5 and 1.1 were observed. Ad-
ditionally, out of 46 probes only 9 were down-regulated 
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Table 1. Transcripts responsive to treatment with doxorubicin*
Probe ID NCBI accession no. Gene ID Gene name Fold change**
4230201 NM_000389.2 1026 CDKN1A 2.8
6480059 NM_001613.1 59 ACTA2 2.0
2640719 NR_001445.1 125050 RN7SK 1.8
990176 NR_001445.1 125050 RN7SK 1.8
1660437 U62823 HS.545589 1.7
1240553 NM_014454.1 27244 SESN1 1.7
2600463 NM_003842.3 8795 TNFRSF10B 1.6
5690554 NM_003620.2 8493 PPM1D 1.6
5420538 NM_033285.2 94241 TP53INP1 1.6
5570678 NM_015920.3 51065 RPS27L 1.6
3520092 NM_138765.2 581 BAX 1.6
3520743 NM_012396.3 23612 PHLDA3 1.6
4730711 AK092074 HS.193406 1.6
670255 NM_001924.2 1647 GADD45A 1.5
4880673 NM_001924.2 1647 GADD45A 1.5
4280482 NM_018370.2 55332 DRAM 1.5
650241 NM_016545.4 51278 IER5 1.5
4480288 NM_022767.2 64782 ISG20L1 1.4
4390300 NM_005749.2 10140 TOB1 1.4
2490215 NM_145263.2 132671 SPATA18 1.4
1010487 NM_006763.2 7832 BTG2 1.4
3520020 NM_001037333.1 26999 CYFIP2 1.4
4230196 NM_002266.2 3838 KPNA2 1.3
5290475 NM_078467.1 1026 CDKN1A 1.3
6510553 NM_005224.2 1820 ARID3A 1.2
4480519 NM_018217.1 55741 EDEM2 1.2
20471 CD706077 HS.572121 1.2
3940762 AK057677 HS.532698 1.2
6550327 NM_006502.1 5429 POLH 1.2
780168 NM_213595.1 23479 ISCU 1.2
150095 NM_001031685.2 7159 TP53BP2 1.2
3890300 NM_018457.2 54458 PRR13 1.1
1820615 NM_018910.2 56141 PCDHA7 1.1
2710341 NM_183079.2 5621 PRNP 1.1
1300762 NM_018234.2 55240 STEAP3 1.1
6060358 AW301107 HS.541717 1.0
7320301 NM_001295.2 1230 CCR1 0.9
6590082 AW183894 HS.542993 0.9
2510731 NM_018233.3 55239 OGFOD1 0.9
2510731 NM_018233.3 55239 OGFOD1 0.9
1980768 NM_005067.5 6478 SIAH2 0.9
2630739 BX106991 HS.154948 0.9
450615 NM_005953.2 4502 MT2A 0.8
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from about 0.96 to 0.8. The changes of expression of 
transcripts in the 14G2a-treated samples were even more 
restricted, when compared to control cells (Table 2). 
None of the transcripts were increased more than 1.5-
fold. The PHLDA1 gene expression was changed 1.4-
fold, followed by JUN (1.3-fold). Some transcripts were 
decreased below 0.8-fold, including that of ID1, IGFBP4, 
MSX1, TLX2 and 3 sequences (C8ORF13, LOC389816, 
C9ORF7). Based on ontological classification analyses 
some genes were grouped according to their involve-
ment into particular biological functions (see Table 3 
for more details on gene ontology terms). Hence, some 
DOX-responsive genes were linked to: induction and 
positive regulation of cell death (including apoptosis), 
DNA metabolic processes, involvement in cell cycle, 
negative regulation of cell proliferation, and response to 
UV. On the contrary only one and unique gene ontology 
term was assigned to the 14G2a-responsive genes, i.e., 
regulation of RNA metabolic processes, as compared to 
the DOX-responsive genes. Based on the gathered data, 
we can conclude that although overall a restricted num-
ber of genes responded to the drugs tested in our model 
and changes of the most of the transcripts are limited, 
several interesting candidates can be selected for further 
analyses.
RT-PCR and western blot analyses of selected 
doxorubicin-responsive genes
In order to verify some changes of gene expres-
sion in the DOX-treated IMR-32 cells, we selected 
CDKN1A [cyclin-dependent kinase inhibitor 1A (p21, 
Cip1)], TNFRSF10B (tumor necrosis factor receptor 
superfamily, member 10B), RPS27L (ribosomal pro-
tein S27-like), SESN1 (sestrin 1), PPM1D (protein 
phosphatase, Mg2+/Mn2+ dependent, 1D) as exam-
ples of the genes that were up-regulated more than 
1.5-fold in the microarrays. We tested levels of their 
transcripts in IMR-32 cells treated with 15 nM and 30 
nM DOX for 24 h using semiquantitative RT-PCR (as 
Figure 1. Hierarchal cluster analysis of genes affected by the tested drugs in the experimental groups of IMR-32 cells was performed 
with dChip software using Euclidean distance and average linkage method. 
Genes and transcriptional forms responsive to (A) DOX (15 nM, 24 h) and (B) 14G2a (40 mg/ml, 24 h) with ANOVA at FDR <5% are shown. 
Intensity of the color is proportional to the fold change (see the bars below the images of the clusters).
6020735 NM_016095.1 51659 GINS2 0.8
2940142 NM_033259.2 94032 CAMK2N2 0.8
770162 NM_001006682.1 474343 SPIN2B 0.8
*Transcripts of genes and particular transcriptional forms of IMR-32 cells that were responsive to treatment with 15 nM doxorubicin for 24 h were 
shown, as compared to control cells (ANOVA at FDR <5%).**The fold change reflects the ratio of the values of signals from DOX-treated cells and 
control cells.
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compared to normal cells). The transcript of ACTB 
was also measured in the samples and used for signal 
normalization. For all 5 aforementioned transcripts we 
observed an increase in signal intensity for the samples 
of RNA isolated from IMR-32 cells treated with 30 
nM DOX for 24 h, while the changes in the samples 
of RNA from cells treated with 15 nM DOX were 
rather small and not always conclusive (see Fig. 2 A, 
B). Then, for SESN1, PPM1D, and RPS27L, we ana-
lyzed levels of transcripts for five time points, i.e., 8, 
16, 24, 32, 48 h using samples of RNA isolated from 
IMR-32 cells treated with 30 nM DOX, as compared 
to control cells (see Fig. 2C). For the transcript of 
SESN1 an increase was clearly observed for all time 
points tested, while expression of the other two genes 
was consistently up-regulated from 24 h. Additionally, 
a western blot technique was applied to measure levels 
of proteins in the samples from IMR-32 cells treated 
with 15 nM and 30 nM DOX for 24 h, as compared 
to control cells. Signals from detection of GAPDH 
were used for protein normalization in the samples 
(Fig. 3). Only for RPS27L, we could observe increase 
in the protein levels for both concentration of DOX 
used (Fig. 3A). A level of PPM1D was increased 
only in samples treated with 15 nM DOX (Fig. 3C), 
while it was decreased along with sestrin 1 in samples 
treated with 30 nM DOX (Fig. 3B,C, pairwise t tests 
between controls and DOX-treated samples did not 
show statistical significance of the measured changes 
of levels of RPS27L, PPM1D, and sestrin 1). Based 
on the results of the experiments, we could confirm 
that DOX increased expression of transcripts of the 
five selected genes. However, additional experiments 
(e.g., performed for longer time points of incubation 
of cells with DOX) are necessary to establish effects 
of DOX on the expression of the genes on the pro-
tein levels.
Table 2. Transcripts responsive to treatment with the 14G2a mAb*
Probe ID NCBI accession no. Gene ID Gene name Fold change**
5900725 NM_007350.3 22822 PHLDA1 1.4
6510367 NM_002228.3 3725 JUN 1.3
1030348 NM_004064.2 1027 CDKN1B 1.2
5340504 NM_004842.2 9465 AKAP7 1.2
70270 NM_194324.1 286527 MGC39900 1.2
3140603 NM_003174.3 6840 SVIL 1.2
630240 NM_177532.3 166824 RASSF6 1.2
6250376 NM_001017975.3 164045 HFM1 1.1
1580626 NM_013398.1 7767 ZNF224 0.9
6660201 NM_000159.2 2639 GCDH 0.9
2900379 NM_001357.3 1660 DHX9 0.9
7200435 NM_005170.2 430 ASCL2 0.9
1580719 NM_022065.4 63892 THADA 0.9
2510731 NM_018233.3 55239 OGFOD1 0.9
2510731 NM_018233.3 55239 OGFOD1 0.9
3120431 NM_000883.2 3614 IMPDH1 0.9
5860358 NM_138793.2 124583 CANT1 0.8
50286 NM_030636.2 80820 EEPD1 0.8
6180402 XR_017492.1 644330 LOC644330 0.8
7380348 NM_018400.3 55800 SCN3B 0.8
2100750 NM_002014.2 2288 FKBP4 0.8
670386 NM_181353.1 3397 ID1 0.8
4010184 NM_053279.1 83648 C8ORF13 0.8
2140541 NM_001013653.1 389816 LOC389816 0.7
7510414 NM_001552.2 3487 IGFBP4 0.7
1010333 NM_002448.3 4487 MSX1 0.7
1440050 NM_173691.2 286262 C9ORF75 0.7
6100370 NM_016170.3 3196 TLX2 0.7
*Transcripts of genes and particular transcriptional forms of IMR-32 cells that were responsive to treatment with the 14G2a mAb (40 mg/ml) for 
24 h were shown, as compared to control cells (ANOVA at FDR <5%). **The fold change reflects the ratio of the values of signals from 14G2a-
treated cells and control cells.
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Qt-RT-PCR analyses of selected 14G2a-responsive genes
Previously, we reported that in IMR-32 cells treated 
with 14G2a both transcript and protein levels of the 
PHLDA1 gene (pleckstrin homology-like domain, fam-
ily A, member 1) were statistically meaningfully increased 
(Horwacik et al., 2013). In order to verify some additional 
changes of transcripts in the 14G2a-treated IMR-32 cells, 
we selected 3 genes that were up-regulated, i.e., JUN (jun 
oncogene), SVIL (supervillin), RASSF6 (Ras association 
(RalGDS/AF-6) domain family member 6) and 2 genes 
that were down-regulated in the microarray analysis, i.e., 
ID1 (inhibitor of DNA binding 1, dominant negative he-
lix-loop-helix protein) and TLX2 (thyroid adenoma asso-
ciated). Also, we measured levels of the CDKN1A gene 
in the cells. Qt-RT-PCR was applied to quantify levels 
Table 3. Examples of gene ontology (GO) terms for the list of DOX- and 14G2A-responsive genes*
GO term Numberof genes Genes
DOX-responsive genes
GO:0012502
induction of programmed cell death 7
CDKN1A, TNFRSF10B, TP53BP2, BAX,RPS27L, PHLDA3, 
TP53INP1
GO:0043067
regulation of programmed cell death 9
CDKN1A, TNFRSF10B, BTG2, TP53BP2, BAX, RPS27L, PRNP, 
PHLDA3, TP53INP1
GO:0043068
positive regulation of programmed cell death 7
CDKN1A, TNFRSF10B, TP53BP2, BAX, RPS27L, PHLDA3, 
TP53INP1
GO:0006259
DNA metabolic process 7 GINS2, POLH, BTG2, BAX, RPS27L, KPNA2, GADD45A
GO:0008285
negative regulation of cell proliferation 6 CDKN1A, PPM1D, BTG2, BAX, SESN1, TOB1
GO:0000086
G2/M transition of mitotic cell cycle 3 CDKN1A, PPM1D, GADD45A
GO:0051329
interphase of mitotic cell cycle 4 CDKN1A, PPM1D, KPNA2, GADD45A
GO:0009411
response to UV 3 CDKN1A, POLH, BAX
14G2a-responsive genes
GO:0051252
regulation of RNA metabolic process 8 ASCL2, DHX9, CDKN1B, MSX1, ID1, ZNF224, JUN, TLX2
*P<0.01, Fisher’s exact test
Figure 2. Effects of doxorubicin (15 nM and 30 nM) on expres-
sion of transcripts of selected responsive genes. 
RT-PCR was used to measure effects of doxorubicin (15 nM and 30 
nM) on transcripts of SESN1, CDKN1A, RPS27L, PPM1D, and TNFS-
F10B in the cell cultures of IMR-32 after 24 h (A, B), while tran-
scripts of SESN1, RPS27L, PPM1D were also verified after addition of 
30 nM DOX for 8, 16, 24, 32, 48 h (C). ACTB gene expression was 
used as a reference. Products of RT-PCR were resolved with aga-
rose gel electrophoresis (one of three independent experiments is 
shown).
Figure 3. Effects of doxorubicin (15 nM and 30 nM) on expres-
sion of proteins of selected responsive genes. 
Levels of RPS27L (A), sestrin 1 (B), and PPM1D (C) were measured 
in the cell cultures of IMR-32 24 h after addition of the drug with 
western blot. GAPDH protein expression was used as a reference 
(one of three independent experiments was shown). Data on the 
graphs are presented as means from three independent experi-
ments (±SEM) and calculated versus control values, set as 1 (black 
baseline). T tests (control samples vs. treated samples) did not 
show statistical significance.
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of the transcripts in IMR-32 cells treated with 40 μg/
ml of 14G2a for 6, 16, 24, 48 h (Fig. 4 A–F). The tran-
script of EF2 was used for signal normalization in the 
samples. The transcript of JUN was statistically signifi-
cantly up-regulated in RNA samples of IMR-cells incu-
bated with the 14G2a mAb for 6, 16, 48 h (P<0.05, for 
pairwise t tests between the control and treated samples). 
The transcripts of SVIL and RASSF6 were increased 
only for 48 h (P<0.05, for pairwise t tests between the 
control and treated samples), while for the time point of 
6 h both transcripts were down-regulated (P<0.05, for 
pairwise t tests between the control and treated sam-
ples). The transcripts of ID1 and TLX2 were shown to 
be down-regulated for all 4 time points tested (for most 
of the time points evaluated P<0.05 was calculated using 
pairwise t tests between the control and treated samples). 
Additionally, we showed that the transcript of CDKN1A 
was statistically significantly decreased upon the treat-
ment with the 14G2a mAb for 6 and 16 h. The data 
gathered allowed us to conclude that qt-RT-PCR results 
confirmed decrease of the transcripts for ID1 and TLX2 
shown by the microarrays. The increase of the transcript 
of JUN was shown for 6, 16, 48 h, but not for 24 h 
as reported in the microarray experiments. Additionally, 
meaningful opposite effects, i.e., a decrease for the 6 h 
time point and an increase for the 48 h time point, were 
observed for the transcripts of SVIL and RASSF6. Fi-
nally, although direct comparison of changes in the tran-
script of CDKN1A were not performed for DOX- and 
14G2a-treated cells contrasting effects can be observed 
(Fig. 2 and Fig. 4), which require verification by side-by 
side sample analysis.
Effects of doxorubicin, topotecan and the 14G2a mAb 
on expression of NDUFAF2 and MYCN
We have previously shown that the increase of tran-
script and protein of PHLDA1 in 14G2a-treated IMR-
32 cells is correlated with a decrease of two oncogen-
ic proteins i.e., aurora A (in whole cell extracts) and 
MYCN (in cytoplasmic and nuclear fractions) (Horwacik 
et al., 2013). Also, cytotoxicity induced with 14G2a in 
IMR-32 cells was accompanied by rise in activity of 
caspases 3 and 7 (Horwacik et al., 2013; Kowalczyk et 
al., 2009). Thus, we extended our research to correlate 
levels of MYCN and a novel NDUFAF2 [(NADH de-
hydrogenase (ubiquinone) complex I, assembly factor 
2)] gene encoding for a mimitin protein (MYC-induced 
mitochondrial protein). We treated IMR-32 cells with 
two cytotoxic drugs, DOX and TPT, which are used for 
neuroblastoma treatment in clinics and were previously 
shown by us to act synergistically with 14G2a on IMR-
32 cells (Kowalczyk et al., 2009). Again cells treated with 
the 14G2a mAb were included. We showed that MYCN 
and mimitin are expressed in IMR-32 and KELLY (both 
MYCN-amplified) neuroblastoma cell lines, contrasting 
to a SK-N-SH (a MYCN-non-amplified) neuroblastoma 
cell line, in which no MYCN was detected and lower 
intensity of the band of mimitin was measured (Fig. 
5A). Also, in IMR-32 we confirmed that no MYC pro-
tein was detected (there was no MYC transcript as well, 
data not shown). To compare cytotoxic effects of DOX 
and TPT on expression of the genes, we selected con-
centration of 17 nM DOX and 2 nM TPT that caused 
reduction of cell viability to about 70% of control cells 
after 48 h (measured by a MTT test, data not shown). 
Figure 4. Qt-RT-PCR analysis showing relative mRNA levels of selected genes in IMR-32 cells upon 6, 16, 24 and 48 hours of 14G2a 
mAb treatment (40 μg/ml). 
JUN (A), SVIL (B), RASSF6 (C), ID1 (D), TLX2 (E), CDKN1A (F). EF-2 cDNA was used as a reference. Data are presented as means of triplicates 
from four to five independent experiments (±SEM) and calculated versus control values, set as 1 (black baseline). ANOVA shows statisti-
cally significant changes of all levels of gene expression in time in IMR-32 cells. P-values for t test (control samples vs. treated samples) 
were as follows: P<0.05 (*), P<0.01 (**), P<0.001 (***).
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Western blot analysis of levels of mimitin and MYCN 
in DOX- and TPT-treated IMR-32 cells did not reveal 
their considerable changes (Fig. 5B, a result from a sin-
gle experiment is shown). However, when we analyzed 
expression of the transcripts of NDUFAF2 and MYCN 
by qt-RT-PCR in the 14G2a-treated cells, we measured 
a statistically meaningful decrease in the levels of both 
transcripts (Fig. 5C, D). Furthermore, we used western 
blot to show that a decrease in the level of MYCN is 
correlated with a decrease of the level of mimitin in 
whole cell extracts from the 14G2a-treated IMR-32 cells 
at 24 and 48 h (P<0.05, for mimitin by a t test, controls 
vs. 14G2a-treated samples for 48 h, Fig. 5E, F).
DISCUSSION
Gene expression signatures of tumor cells are exten-
sively studied to better understand differences between 
transformed and normal cells, but also in quest for diag-
nostic, or prognostic markers, and new targets for treat-
ment of patients with cancer. Thus, we aimed to gain 
more insight into changes of transcriptome of IMR-32 
cells treated with 14G2a and to compare the effects in-
duced with the antibody and doxorubicin. In general, 
only minor changes in levels of the analyzed transcripts 
were observed between control, untreated cells, and 
14G2a-treated cells in our whole-genome transcriptome 
studies, suggesting that in the next step we should fo-
cus on detailed proteome analyses. However, it should 
be stressed that the experiments allowed to find correla-
tions between 14G2a and genes important for neuroblas-
toma biology. For instance, ID1 and TLX2 were down-
regulated in the arrays and in the following qt-RT-PCR 
analyses. TLX2 and PHOX2B are transcription factors 
important for differentiation of autonomic nerve cells 
(Borghini et al., 2006). Also, ID-1,-2, and -3 proteins are 
involved in keeping neuroblastoma cells in undifferenti-
ated state as shown by Jögi and colleagues (Jögi et al., 
2002).
Based on the GO analysis, the 2 aforementioned 
genes and 6 others (ASCL2, DHX9, CDKN1B, MSX1, 
ZNF224, JUN) are involved in regulation of RNA meta-
bolic processes (GO: 0051252). Literature search allowed 
us to establish that ASCL2, a transcription factor protein 
involved in WNT signaling and miR-200s participate in 
regulation of transitions between mesenchymal and epi-
thelial phenotypes (Tian et al., 2014). Also, MSX1, yet 
another transcription factor, was shown to be involved 
in Delta-Notch and WNT signaling in neuroblastoma 
(Revet et al., 2008; Revet et al., 2010). Recently, Chen and 
colleagues, showed that DHX9 (RNA helicase A) and its 
nuclear localization is involved in pro-apoptotic function 
of KIF1Bβ, a protein with tumor-suppressor properties 
Figure 5. Effects of DOX, TPT and the 14G2a mAb on expression of NDUFAF2 and MYCN were analyzed in IMR-32 cells. 
(A) Western blot analysis of mimitin and MYCN protein levels in MYCN-amplified IMR-32, KELLY cells and MYCN-non-amplified SK-N-SH 
cells. (B) Expression of mimitin and MYCN in IMR-32 cells treated with 17 nM DOX and 2 nM TPT for 24 and 48 h (one experiment is 
shown). Qt-RT-PCR was used to measure levels of NDUFAF2 (C) and MYCN (D) 24 and 48 h after treatment with 14G2a (40 mg/ml). The 
transcript of E2F was measured as a reference. Data are presented as means of triplicates from three independent experiments (±SEM) 
and calculated versus control values, set as 1 (black baseline). ANOVA shows statistically significant changes of MYCN expression levels 
in time in IMR-32 cells and no statistically significant changes of NDUFAF2 expression levels in time. P-values for t test (control samples 
vs. treated samples) were P<0.05 (*), P<0.01 (**). Changes in mimitin (E) and MYCN (F) expression in IMR-32 cells after treatment with 40 
mg/ml of 14G2a for 6, 16, 24, 48 h (a-tubulin or GAPDH expression was measured as a reference for western blot analyses). Data on the 
graphs are presented as means from three independent experiments (±SEM) and calculated versus control values, set as 1 (black base-
line). P-value for t test (control samples vs. treated samples) is P<0.05 (*).
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that is encoded in a region 1p36.2 lost in a subset of 
neuroblastomas (Chen et al., 2014). Moreover, DHX9 
was among ten genes with recurrent gene mutations that 
correlated with pathways deregulation and clinical out-
comes among patients with lung adenocarcinoma who 
never-smoked (Sun et al., 2014). Finally, ZNF224 was 
implicated in apoptosis induced after DNA damage in 
leukemia cells (Montano et al., 2013).
Two genes, SVIL and RASSF6 showed a decrease 
in expression for the 6 h time point and an increase 
of expression for the 48 h time point in samples of 
14G2a-treated IMR-32 cell, thus stressing the need for 
detailed analyses of the 14G2a-responsive genes yielded 
by microarrays. They are necessary to verify the results 
generated with the whole genome analysis approach. 
Additionally, analysis of both mRNA and protein levels 
in samples collected for additional time points or other 
14G2a-sensitive neuroblastoma cell lines are warranted 
to elucidate roles of the selected genes in our model. 
Of interest to us is a report on a role of RASSF6 as a 
tumor suppressor and its function in P21 accumulation, 
induction of G1 cell cycle arrest, and apoptosis in clear 
cell renal cell carcinoma (Liang et al., 2014).
Previously we reported that the PHLDA1 transcript 
and protein levels were up-regulated in our model. 
Also, the P53 protein was up-regulated in the IMR-32 
cells treated with 14G2a from 2 h and its nuclear ac-
cumulation was shown from 6 h (Horwacik et al., 2013). 
Both proteins are involved in interactions with aurora A 
(Johnson et al., 2011). The total level of the oncogenic 
protein and the extent of its phosphorylation at Thr288 
were decreased in the 14G2a-treated IMR-32 and LA-N-
1 cells (Horwacik et al., 2013). In addition, in the mi-
croarrays data the transcript of SCN3B, a P53 inducible 
gene, (Adachi et al., 2004) was down-regulated in the 
14G2a-treated cells. Again, this highlights the need for 
analysis of samples collected at additional time points. 
Also, the transcript of FKBP4 (FKBP54) encoding a 
chaperone protein (Shim et al., 2009) was decreased in 
the microarrays. This adds to our previous findings that 
HSP40 and HSP70 proteins were decreased in IMR-32 
cells treated with 14G2a (Horwacik et al., 2013). Thus, 
we can conclude that the data from the microarray and 
the qt-RT-PCR analyses of transcriptome of IMR-32 
cells after 14G2a extend our knowledge on mechanism 
of action of the antibody on the cell line.
Yet another transcription factor, MYCN, was de-
creased in cytoplasmic and nuclear extracts of IMR-32 
cells after 14G2a treatment (Horwacik et al., 2013). Here, 
we add data from qt-RT-PCR showing that down-regu-
lation of MYCN mRNA correlates with decreased levels 
of the protein in whole cell extracts of IMR-32 after the 
mAb addition. Interestingly, mRNA and protein levels 
of NDUFAF2 are also down-regulated in IMR-32 cells 
treated with 14G2a. The novel NDUFAF2 gene encod-
ing for mimitin was shown to be directly stimulated by 
MYC and involved in proliferation of esophageal squa-
mous cell carcinoma (Tsuneoka et al., 2005). Its functions 
are still elucidated. The mimitin protein was showed to 
act as a molecular chaperone for mitochondrial complex 
I assembly (Ogilvie et al., 2005). On the other hand, in 
2013 Schlehe and colleagues showed that the protein de-
ficiency reduced complex-1 activity, increased levels of 
oxidative stress and deletion of mitochondrial DNA, but 
was dispensable for maturation of the complex (Schlehe 
et al., 2013). Moreover, over-expression of mimitin was 
reported to indirectly correlate with reduction of activity 
of caspase 3/7 in HepG2 cells (Wegrzyn et al., 2009). 
In our model, the observed reduction of mimitin protein 
correlates with our previous report on a rise in caspase 
3/7 activity at 48 h and 72 h of IMR-32 treatment with 
14G2a (Horwacik et al., 2013). This may indicate a role 
of mimitin in observed apoptosis and encourages further 
research on the involvement of the protein in our mod-
el. Finally, as no MYC is expressed in MYCN-amplified 
IMR-32 neuroblastoma cells and the levels of both 
MYCN and mimitin are reduced in the 14G2a-treated 
IMR-32 cells, it might be of interest to further investi-
gate whether the transcription factor is directly involved 
in regulation of expression of the NDUFAF2 gene. Re-
cently, Murphy and colleagues showed that in neuro-
blastoma cell lines MYCN binds more selectively to the 
CATGTG motif than to the classic E-box CACGTG 
motif. Also, other motifs, i.e., CATTTG, CATCTG, 
CAACTG were bound by MYCN in MYCN-amplified 
cells. (Murphy et al., 2009). On that note, possible role 
of MYCN in the NDUFAF2 gene expression could be 
investigated.
To summarize, based on the reported data from our 
experiments we gained more insight into effects of 
14G2a on IMR-32 neuroblastoma cells and selected new 
and interesting genes for further investigation.
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